A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas

Cancer Research

Volumn 64, Issue 14, 2004, Pages 4870-4874

  De Lorenzo, Claudia ^a   Arciello, Angela ^a   Cozzolino, Rosanna ^a   Palmer, Donald B ^b   Laccetti, Paolo ^a   Piccoli, Renata ^a   D'Alessio, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HERB HRIBONUCLEASE; RIBONUCLEASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG PURIFICATION; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG STABILITY; FEMALE; HUMANS; IMMUNOTOXINS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; RIBONUCLEASES;

EID: 3142773417     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3717     Document Type: Article

References (35)

1. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2003;2:52-62.
2. Milenic DE. Monoclonal antibody-based therapy strategies: providing options for the cancer patient. Curr Pharm Des 2002;8:1749-64.
3. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750-63.
4. Pastan I, FitzGerald D. Recombinant toxins for cancer treatment. Science 1991;254:1173-7.
5. Reiter Y, Pastan I. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol 1998;16:513-20.
6. Weiner LM, O'Dwyer J, Kitson J, et al. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A immunoconjugate. Cancer Res 1989;49:4062-7.
7. Schindler J, Sausville E, Messmann R, Uhr JW, Vitetta ES. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. Curr Opin Oncol 2001;13:168-75.
8. Schnell R, Vitetta E, Schindler J, et al. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia 2000;14:129-35.
9. Soler-Rodriguez AM, Ghetie MA, Oppenheimer-Marks N, Uhr JW, Vitetta ES. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Exp Cell Res 1993;206:227-34.
10. Baluna R, Vitetta ES. An in vivo model to study immunotoxin-induced vascular leak in human tissue. J Immunother 1999;22:41-7.
11. Rybak SM, Newton DL. Natural and engineered cytotoxic ribonucleases: therapeutic potential. Exp Cell Res 1999;253:325-35.
12. De Lorenzo C, Nigro A, Piccoli R, D'Alessio G. A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells. FEBS Lett 2002;516:208-12.
13. Zewe M, Rybak SM, Dubel S, et al. Cloning and cytotoxicity of a human pancreatic RNase immunofusion. Immunotechnology 1997;3:127-36.
14. Suwa T, Ueda M, Jinno H, et al. Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody-ribonuclease conjugate on human cancer cells. Anticancer Res 1999;19:4161-5.
15. Stocker M, Tur MK, Sasse S, Krussmann A, Barth S, Engert A. Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells. Protein Expr Purif 2003;28:211-9.
16. Christensen ME. The EGF receptor system in head and neck carcinomas and normal tissues. Immunohistochemical and quantitative studies. Dan Med Bull 1998;45:121-34.
17. Moos T, Morgan EH. Transferrin and transferrin receptor function in brain barrier systems. Cell Mol Neurobiol 2000;20:77-95.
18. Ishida T, Tsujisaki M, Hanzawa Y, et al. Significance of erbB-2 gene product as a target molecule for cancer therapy. Scand J Immunol 1994;39:459-66.
19. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
20. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000;77:25-79.
21. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55.
22. Lohrisch C, Piccart M. HER2/neu as a predictive factor in breast cancer. Clin Breast Cancer 2001;2:129-35.
23. Griffiths AD, Williams SC, Hartley O, et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 1994;13:3245-60.
24. Vaughan TJ, Williams AJ, Pritchard K, et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 1996;14:309-14.
25. Sheets MD, Amersdorfer P, Finnern R, et al. Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci USA 1998;95:6157-62.
26. De Lorenzo C, Palmer DB, Piccoli R, Ritter MA, D'Alessio G. A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res 2002;8:1710-9.
27. Evan GI, Lewis GK, Ramsay G, Bishop JM. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol 1985;5:3610-6.
28. Russo N, de Nigris M, Ciardiello A, Di Donato A, D'Alessio G. Expression in mammalian cells, purification and characterization of recombinant human pancreatic ribonuclease. FEBS Lett 1993;333:233-7.
29. Nissim A, Hoogenboom HR, Tomlinson IM, et al. Antibody fragments from a "single pot" phage display library as immunochemical reagents. EMBO J 1994;13:692-8.
30. Bartholeyns J, Wang D, Blackburn P, Wilson G, Moore S, Stein WH. Explanation of the observation of pancreatic ribonuclease activity at pH 4.5. Int J Pept Protein Res 1977;10:172-5.
31. Blank A, Sugiyama RH, Dekker CA. Activity staining of nucleolytic enzymes after sodium dodecyl-sulfate-polyacrylamide gel electrophoresis: use of aqueous isopropanol to remove detergent from gels. Anal Biochem 1982;120:267-75.
32. Rovero S, Amici A, Carlo ED, et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000;165:5133-42.
33. Merlin JL, Barberi-Heyob M, Bachmann N. In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines. Ann Oncol 2002;13:1743-8.
34. Saxena SK, Rybak SM, Winkler G, et al. Comparison of RNases and toxins upon injection into Xenopus oocytes. J Biol Chem 1991;266:21208-14.
35. Di Carlo E, Diodoro MG, Boggio K, et al. Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab Invest 1999;79:1261-9.